Spero Therapeutics's total assets for Q3 2024 were $135.16M, a decrease of -9.82% from the previous quarter. SPRO total liabilities were $69.65M for the fiscal quarter, a 0.39% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.